{"url_path":"/sec/nuvb/8-k/2026-06-30/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-30","source_url":"https://www.sec.gov/Archives/edgar/data/1811063/0001193125-26-290823-index.html","accession_number":"0001193125-26-290823","cik":"0001811063","ticker":"NUVB","issuer_name":"Nuvation Bio Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1811063/0001193125-26-290823-index.html","primary_entity_key":"0001811063","primary_entity_name":"Nuvation Bio Inc."},"word_count":226,"has_tables":true,"body_markdown":"Item 9.01 Financial Statements and Exhibits.\n\n(d) Exhibits\n\n \n\nExhibit\nNo.\n  \n\nDescription\n\n1.1\n  \n[Underwriting Agreement, dated June 25, 2026, by and among the Company, Jefferies LLC, Citigroup Global Markets Inc., and Cantor Fitzgerald & Co., as representatives of the Underwriters.](d81296dex11.htm)\n\n4.1\n  \n[Base Indenture, dated June 30, 2026, by and between the Company and U.S. Bank Trust Company, National Association, as Trustee.](d81296dex41.htm)\n\n4.2\n  \n[First Supplemental Indenture, dated June 30, 2026, by and between the Company and U.S. Bank Trust Company, National Association, as Trustee (including the form of 0.75% Convertible Senior Note due 2032).](d81296dex42.htm)\n\n5.1\n  \n[Opinion of Cooley LLP.](d81296dex51.htm)\n\n23.1\n  \n[Consent of Cooley LLP (included in Exhibit 5.1).](d81296dex51.htm)\n\n10.1\n  \n[First Amendment to Revenue Interest Financing Agreement, dated June 24, 2026, by and between the Company and Sagard Healthcare Partners Funding Borrower SPE 2, LP.](d81296dex101.htm)\n\n10.2\n  \n[Form of Confirmation for Capped Call Transactions.](d81296dex102.htm)\n\n99.1\n  \n[Launch Press Release of the Company dated June 25, 2026.](d81296dex991.htm)\n\n99.2\n  \n[Pricing Press Release of the Company dated June 25, 2026.](d81296dex992.htm)\n\n104\n  \nCover Page Interactive Data File (embedded within the Inline XBRL document).\n\n \n\n5\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \nNUVATION BIO INC.\n\nDate: June 30, 2026\n \n\n \nBy:\n \n\n /s/ Philippe Sauvage\n\n \n\n \n\n \n Name: Philippe Sauvage\n\n \n\n \n\n \n Title: Chief Financial Officer"}